Cargando…

A first case report of clinical response to targeted therapy in a patient with primary myoepithelial carcinoma of the lung harboring EGFR exon 19 deletion

BACKGROUND: Primary myoepithelial carcinoma of the lung is a rare subtype in lung cancer. Comprehensive molecular profiling of myoepithelial carcinoma of the lung is absent, neither was clinical evidence of targeted therapy available for this disease. Therefore, the optimal treatment regimen of this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Xiaohong, Lin, Xinqing, Liu, Ming, Qin, Yinyin, Ouyang, Ming, Li, Shiyue, Gu, Yingying, Chen, Shuyin, Xiang, Jianxing, Zhou, Chengzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275596/ https://www.ncbi.nlm.nih.gov/pubmed/32505185 http://dx.doi.org/10.1186/s13000-020-00986-0

Ejemplares similares

Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease
por: Xie, Xiaohong, et al.
Publicado: (2019)

Case Report: Fatal Multiorgan Failure and Heterochronous Pneumonitis Following Pembrolizumab Treatment in a Patient With Large-Cell Neuroendocrine Carcinoma of Lung
por: Xie, Xiaohong, et al.
Publicado: (2021)

Combination therapy of first and third generation EGFR-TKIs for an advanced lung adenocarcinoma patient harboring EGFR mutations and amplification: a case report
por: Chen, Yongxing, et al.
Publicado: (2020)

Extracranial abscopal effect induced by combining immunotherapy with brain radiotherapy in a patient with lung adenocarcinoma: A case report and literature review
por: Lin, Xinqing, et al.
Publicado: (2019)

A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung
por: Xie, Zhanhong, et al.
Publicado: (2019)

Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer
por: Xie, Xiaohong, et al.
Publicado: (2021)

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
por: Lin, Xinqing, et al.
Publicado: (2020)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
por: Wang, Yurong, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
por: Deng, Haiyi, et al.
Publicado: (2021)

Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report
por: Xie, Zhanhong, et al.
Publicado: (2019)

Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015)

The clinical analysis of pulmonary lymphoepithelioma-like carcinoma with epithelioid granuloma
por: Gao, Guoying, et al.
Publicado: (2020)

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
por: Chen, Dan, et al.
Publicado: (2016)

Management and Prognosis of Interstitial Lung Disease With Lung Cancer (ILD-LC): A Real-World Cohort From Three Medical Centers in China
por: Xiaohong, Xie, et al.
Publicado: (2021)

MicroRNA Signature of Lung Adenocarcinoma with EGFR Exon 19 Deletion
por: Ju, Lixia, et al.
Publicado: (2017)

Comprehensive characterization reveals sputum supernatant as a valuable alternative liquid biopsy for genome profiling in advanced non-small cell lung cancer
por: Xie, Xiaohong, et al.
Publicado: (2022)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Tumor immune microenvironment and mutational analysis of tracheal adenoid cystic carcinoma
por: Wang, Fei, et al.
Publicado: (2020)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Generation and Characterization of a Mouse Model Harboring the Exon-3 Deletion in the Cardiac Ryanodine Receptor
por: Liu, Yingjie, et al.
Publicado: (2014)

Treatment response and safety of immunotherapy for advanced non-small cell lung cancer with comorbid chronic obstructive pulmonary disease: a retrospective cohort study
por: Zhang, Kening, et al.
Publicado: (2022)

Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience
por: Lin, Xinqing, et al.
Publicado: (2021)

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
por: Chen, Yi-Chieh, et al.
Publicado: (2021)

Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies
por: Cortiula, Francesco, et al.
Publicado: (2022)

Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy
por: Lin, Xinqing, et al.
Publicado: (2021)

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
por: Tokudome, Nahomi, et al.
Publicado: (2020)

Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study
por: Lin, Xinqing, et al.
Publicado: (2022)

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
por: Takeda, Masayuki, et al.
Publicado: (2018)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma
por: Dahse, R, et al.
Publicado: (2008)

Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation
por: Tamirat, Mahlet Z., et al.
Publicado: (2019)

Exons deletion of CNKSR2 gene identified in X-linked syndromic intellectual disability
por: Daoqi, Mei, et al.
Publicado: (2020)

PMON115 Long term follow-up of patient with gigantism harboring an exon 2 deletion in the AIP gene
por: Huayllas, Martha Katherine Paniagua, et al.
Publicado: (2022)

Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
por: Zhou, Jinhua, et al.
Publicado: (2023)

Detection of internal exon deletion with exon Del
por: Guo, Yan, et al.
Publicado: (2014)

The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research
por: Meng, Yan, et al.
Publicado: (2022)

Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma
por: Tian, Yingying, et al.
Publicado: (2018)

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
por: Matsuo, Norikazu, et al.
Publicado: (2016)

Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review
por: Watanabe, Naohiro, et al.
Publicado: (2022)

3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma
por: Liu, Guixue, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mv3ic1t8sivs17q99c2dj5p9lo